Biotech focuses on infusing biological processes with technology to improve human, animal, and environmental health. Biotech & Pharma businesses utilize technology to work toward disease prevention, treatment and cure. These businesses also work in Agtech and fuel development. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Odyssey Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $413.6MM | Series D | 9/10/2025 | $213.63MM | $527.3MM | $14.62 | Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG, Wedbush Healthcare Partners | |||||
| ADARx Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $505MM | Series C | 8/9/2023 | $200MM | $827.77MM | $8.32 | Bain Capital Life Sciences, TCGX, Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital, Ascenta Capital, Lilly Asia Ventures, OrbiMed Advisors, SR One Capital Management | |||||
| Tessera Therapeutics | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $587.85MM | Series D | 12/1/2025 | $200MM | $668.33MM | $5.18 | Bill & Melinda Gates Foundation, Regeneron | |||||
| Encoded Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $670.89MM | Series E | 6/24/2021 | $378.09MM | $2.13B | $22.73 | Undisclosed Investors | |||||
| Alamar Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $248.57MM | Series C | 2/26/2024 | $128.27MM | $453.99MM | $7.20 | Sands Capital, Sherpa Healthcare Partners, Pura Vida Investments | |||||
| Loyal | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $236.56MM | Series C | 2/11/2026 | $95.46MM | $614.38MM | $12.26 | Age 1, Baillie Gifford | |||||
| MBX Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $216.64MM | Series C | 8/5/2024 | $63.5MM | $316.71MM | $1.03 | Deep Track Capital, Driehaus Capital Management, T. Rowe Price Associates, Frazier Life Sciences, OrbiMed, Wellington Management | |||||
| Twin Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $304.72MM | Series E | 8/21/2025 | $53MM | $950MM | $13.85 | Maj Invest, Temasek, ICONIQ Growth | |||||
| ArteraAI | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $97.32MM | Series Seed-3 | 2/1/2024 | $82.82MM | $408.31MM | $7.95 | Coatue, Johnson & Johnson Innovation, Koch Disruptive Technologies, Walden Catalyst, TIME Ventures, Breyer Capital, The Factory, Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, Michael Driscoll, Prosperity7 Ventures, EDBI, Wilson Sonsini Goodrich & Rosati, Trium Ventures, Navin Chaddha, Rajiv Khemani, Andrew Tan, Elliott Tan | |||||
| Asimov | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $241.8MM | Series B | 1/5/2023 | $175MM | $1.24B | $92.68 | CPP Investments, Fidelity, KDT, Casdin Capital, Pillar, Andreessen Horowitz, Horizons Ventures | |||||
| Human Longevity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $91.95MM | Series B-1 | 8/21/2024 | $32MM | $185.79MM | $0.31 | TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust | |||||
| Mammoth Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $379.07MM | Series D-3 | 12/2/2025 | $15MM | $1.35B | $13.45 | Undisclosed Investors | |||||
| Eikon Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.16B | Series D | 2/14/2025 | $350.7MM | $1.85B | $5.84 | Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, T. Rowe Price, UC Investments | |||||
| Kailera Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $959.96MM | Series B | 10/14/2025 | $603.18MM | $1.4B | $14.00 | Bain Capital, Adage Capital Management, Canada Pension Plan Investment Board, Invus, Janus Henderson Investors, Perseverance Capital, QIA, Royalty Pharma, Surveyor Capital, T. Rowe Price, Atlas Venture, Bain Capital Life Sciences, RTW Investments, Sirona Capital | |||||
| Prime Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $315.76MM | Series B | 7/13/2021 | $200MM | $1.23B | $4.38 | ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners, Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group, Samsara BioCapital, T. Rowe Price | |||||
| Recursion Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Unlearn | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $135.17MM | Series C | 2/8/2024 | $50MM | $368.17MM | $9.24 | Altimeter Capital Management, Radical Ventures, Mubadala Capital, Wittington Ventures, EPIC Ventures, Necessary Ventures, Insight Partners, 8VC, DCVC | |||||
| BlossomHill Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $173MM | Series B | 2/29/2024 | $100MM | $293.78MM | $3.76 | Colt Ventures, Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules BioVentures Partners, Plaisance Capital Management, H&D Asset Management | |||||
| Frontier Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $255.5MM | Series C | 6/25/2024 | $100MM | $438.18MM | $2.34 | Deerfield Management Company, Droia Ventures, Galapagos NV, DCVC, MPM Capital, RA Capital Management, Deep Track Capital, ArrowMark Partners | |||||
| Owkin | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $279.77MM | Series B-1 | 6/8/2022 | $50MM | $1.46B | $45.70 | Bristol Myers Squibb | |||||
| Triveni Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $297.49MM | Series C | 6/17/2026 | $65.25MM | $423.44MM | $1.26 | Ascenta Capital, Janus Henderson Investors, Deep Track Capital, OrbiMed, Atlas Venture, Viking Global Investors | |||||
| Terray Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $201.97MM | Series B | 10/17/2024 | $120MM | $386.49MM | $6.66 | Bedford Ridge Capital, NVIDIA, Maverick Capital, Goldcrest Capital, Madrona Venture Group, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, Alexandria Venture Investments | |||||
| BillionToOne | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $396.39MM | Series D | 6/21/2024 | $130.47MM | $1.25B | $28.02 | Premji Invest, Neuberger Berman, Adams Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, Fifty Years | |||||
| BioAge | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.42B | Series D | 2/13/2024 | $170MM | $440.23MM | $3.42 | Sofinnova Investments, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Amgen Ventures, Andreessen Horowitz | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.